R-MDDMA is a Safer Analogue of MDMA with Therapeutic Potential.
Maxemiliano V Vargas, Cassandra J Hatzipantelis, Lee E Dunlap, Robert J Tombari, Arabo A Avanes, Sam Vaillancourt, Pierre Llorach, Juliana S Salgado, Boris D Heifets, David E Olson
ACS chemical neuroscience May 6, 2026 Peer reviewed DOI: 10.1021/acschemneuro.5c00891 via PubMed
Summary
R-MDDMA, a methylated analogue of MDMA, shows promise as a safer alternative for treating neuropsychiatric conditions like PTSD and depression. Unlike MDMA, R-MDDMA does not activate certain serotonin receptors or induce negative side effects such as hyperlocomotion. It promotes neuroplasticity in cortical neurons, aids in fear extinction learning, and has sustained antidepressant-like effects, indicating its potential therapeutic benefits.
Study at a glance
| Key finding | R-MDDMA might be a safer MDMA analogue with similar therapeutic properties. |
|---|
Abstract
Recent clinical evidence suggests that racemic 3,4-methylenedioxymethamphetamine (MDMA) might be useful for treating a range of neuropsychiatric diseases including post-traumatic stress disorder (PTSD) and depression. However, concerns about its abuse potential stemming from its monoamine releasing properties have hampered its clinical development. Thus, safer analogues of racemic MDMA with comparable therapeutic effects are highly desirable. Here, we compare the pharmacological effects of MDMA enantiomers with those of its methylated analogue 3,4-methylenedioxy-N,N-dimethylamphetamine (MDDMA). We found that R-MDDMA did not directly activate 5-HT2B receptors, induce serotonin efflux, produce a head-twitch response, impact body temperature, or induce hyperlocomotion at therapeutically relevant doses. However, it still promoted structural neuroplasticity in cortical neurons, facilitated fear extinction learning, and produced sustained antidepressant-like effects. Taken together, our results suggest that R-MDDMA might be a safer MDMA analogue with similar therapeutic properties.